Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.
Authors:
- Kathleen CostelloKCKathleen Costello
- Patricia KennedyPKPatricia Kennedy
- Jo ScanzilloJSJo Scanzillo
- 30 September 2008
- journal article
- research article
- Vol. 10 (9) , 225
Abstract
Patients with multiple sclerosis (MS) face many challenges. One significant challenge is long-term adherence to disease-modifying therapy (DMT). Four of the 6 currently available DMTs involve self-injection, and all cause adverse events of varying degrees of severity. Although effective, the benefit of DMTs is difficult to determine on an immediate basis. Healthcare providers must play a major role in recognizing nonadherence and identifying strategies to promote adherence. We conducted a literature search of the MEDLINE database using the search terms "adherence" and "multiple sclerosis" to gather data from relevant studies investigating adherence among patients with MS. Barriers to maintaining treatment adherence in patients with MS include forgetting the medication, injection anxiety, perceived lack of efficacy, coping with adverse events, and issues with complacency and treatment fatigue. An open and honest healthcare provider-patient relationship is a core element in maintaining motivation and adherence in patients with MS. In addition, continuous education and consistent reinforcement of the value of treatment are essential strategies in the maintenance of treatment adherence. Other strategies to promote adherence include management of treatment expectations and minimization of adverse events. The chronic nature of MS makes treatment adherence challenging in patients with long-standing disease. Patients and healthcare providers need to work together to establish open lines of communication and a trust-based therapeutic relationship to ensure that patients have the knowledge and skills they need to adhere to long-term MS therapy.Keywords
This publication has 19 references indexed in Scilit:
- Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs modelMultiple Sclerosis Journal, 2007
- Adherence to interferon-beta treatment and results of therapy switchingJournal of the Neurological Sciences, 2007
- Pharmacist Intervention to Improve Medication Adherence in Heart FailureAnnals of Internal Medicine, 2007
- Managing Self-Injection Difficulties in Patients with Relapsing-Remitting Multiple SclerosisJournal of Neuroscience Nursing, 2006
- Adherence to MedicationNew England Journal of Medicine, 2005
- Twenty‐four‐month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®)European Journal of Neurology, 2005
- Long-term interferon-β treatment for multiple sclerosisNeurological Sciences, 2003
- Interrupted therapyNeurology, 2003
- Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and infection anxiety on adherence and ability to self-injectAnnals of Behavioral Medicine, 2001
- Localized Lipoatrophy After Glatiramer Acetate Injection in Patients With Remitting-Relapsing Multiple SclerosisArchives of Dermatology, 1999